Novavax (NVAX) Reports Positive Phase 1 Data for COVID-19 Vaccine Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate
August 4, 2020 4:06 PM EDTPhase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax COVID-19 vaccine across two dose levels (5 and 25 µg) in 131 healthy adults ages 18-59 yearsNVX-CoV2373 was generally well-tolerated and had a reassuring safety profileThe vaccine induced neutralization titers in 100% of participants Both 5 µg and 25 µg adjuvanted doses generated peak geometric mean titer (GMT) greater than 1:3,300 Matrix-M adjuvant induced robust polyfunctional CD4+ T cell responsesConference call to be held on Tuesday,... More
